214 results on '"Locke, Frederick L"'
Search Results
2. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
3. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
4. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma
5. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies
6. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma
7. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience
8. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
9. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.
10. Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)
11. Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis
12. Impact of Renally Adjusted Methotrexate Dosing on Safety and Efficacy Outcomes in Allogeneic Hematopoietic Cell Transplant Patients
13. Outcomes of Haploidentical Stem Cell Transplant Recipients with HHV-6 Reactivation Receiving Antiviral Therapy
14. Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US)
15. Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention
16. Minority Patients Receiving CAR T Therapy in the US between 2020−2025: A SEER-Based Projection on Racial Composition and Impact of Proximity to Authorized Treatment Centers
17. Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting
18. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Versus Epcoritamab in Third-Line Diffuse Large B-Cell Lymphoma Patients in the United States
19. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Versus Glofitamab in Third-Line Diffuse Large B-Cell Lymphoma Patients in the United States
20. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience
21. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation
22. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
23. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
24. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma
25. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy
26. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
27. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
28. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma
29. Change in Patients’ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma
30. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy
31. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma
32. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma
33. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
34. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study
35. Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS)
36. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Zuma-7
37. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)
38. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience
39. Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience
40. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
41. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
42. The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
43. Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
44. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience
45. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
46. Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?
47. Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies
48. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy
49. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
50. Lived Experience and Intervention Considerations for Caregivers of Patients Who Receive Cellular Immunotherapy: A Qualitative Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.